[UK] +44 (0)1304 892398 [US] +19782 899035 admin@trn.net

Rob Wallis

30 years of drug discovery and development expertise working with project teams operating from target selection to post-marketing. Expert in Safety Pharmacology, including the implementation of ICHS7A and ICH 7B strategies and the application of safety pharmacology assays early in drug discovery to support target selection and compound nomination. He has a world reputation in the area of drug-induced QT prolongation and non-clinical cardiovascular safety evaluation. He has presented at numerous scientific conferences on all aspects of safety pharmacology.

, ,